FDA Moves Closer to Approving MDMA for PTSD Treatment


The U.S. Food and Drug Administration (FDA) is on the brink of a groundbreaking decision regarding the approval of MDMA, commonly known as ecstasy, for the treatment of post-traumatic stress disorder (PTSD). This follows extensive clinical trials showing promising results in alleviating symptoms of PTSD among participants.

The FDA's Psychopharmacologic Drugs Advisory Committee is set to hold a pivotal meeting today to discuss the potential approval of MDMA-assisted therapy for PTSD. This marks the first formal debate by FDA experts on a psychedelic treatment, reflecting the significant advancements and growing acceptance of psychedelic-assisted therapies in mental health treatment​.

The clinical trials leading up to this decision were rigorous. Two Phase 3 trials, MAPP1 and MAPP2, demonstrated that participants receiving MDMA in conjunction with psychological therapy showed substantial improvements. Approximately 71% of those in the MDMA group no longer met the diagnostic criteria for PTSD by the end of the study, compared to about 48% in the placebo group. Furthermore, 46.2% of the MDMA group met remission criteria, significantly higher than the 21.4% in the placebo group​.

MDMA's therapeutic benefits are thought to stem from its ability to reduce the emotional impact of traumatic memories and enhance feelings of trust and empathy, thereby strengthening the therapeutic relationship and facilitating deeper psychological healing. The studies also reported that while some adverse effects like nausea and anxiety were observed, none were serious​.

Despite its current classification as a Schedule I substance, which denotes a high potential for abuse and no accepted medical use, the success of these trials could lead to a historic approval.

If the FDA grants approval, MDMA would become the first psychedelic-assisted therapy approved in the United States, paving the way for further acceptance and use of psychedelic drugs in medical treatments​​.

The sponsor of the trials, Lykos Therapeutics (formerly MAPS Public Benefit Corporation), has been at the forefront of this research. Their efforts have included comprehensive training for therapists and meticulous study designs to ensure the reliability and safety of the treatment. The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date for August 11, 2024, to decide on the New Drug Application (NDA)​.

This potential approval is seen as a significant step forward in addressing the unmet needs of PTSD patients, many of whom have not found relief through traditional therapies. The upcoming decision by the FDA could revolutionize the treatment landscape for PTSD, offering hope to millions of sufferers​ .


Please enter your comment!
Please enter your name here